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Abstract
Esophagitis is the inflammation of the lining of the esophagus, which is charac-
terized by its swelling and irritation. The esophagus is tubular structure which helps 
in the swallowing, and it links the back of the throat to the stomach. The swelling 
is commonly caused by acid reflux. Sometimes, this swelling can also be caused by 
infections. Infectious esophagitis can be set off by fungi, yeast, viruses, bacteria 
and other types of organisms. Anyone can get infectious esophagitis, but people 
with weakened or comprised immune system are more likely to develop the disease. 
Anyone can get it, but people are more likely to develop it if their immune system 
is weakened or compromised. The purpose of this chapter is to review the clinical 
manifestations, etiology, pathophysiology, histopathology, diagnosis, treatment/
management, prevention, prognosis and other healthcare issues of infectious 
esophagitis.
Keywords: Infectious esophagitis, fungi, yeast, virus, bacteria, diagnosis, treatment, 
prevention
1. Introduction
Esophagitis is the swelling and irritation of the esophagus. Thus esophagitis 
refers to inflammation or injury to the esophageal mucosa. The esophagus is the 
tube that is used in swallowing and it connects the back of the throat to the stom-
ach. There are many causes of esophagitis and essentially the presentation is similar 
which include retrosternal chest pain, heartburn, dysphagia or odynophagia [1, 2]. 
The most common cause of swelling and irritation of the esophagus is stomach acid 
that flows back into the esophagus, called gastroesophageal reflux, which can lead 
to erosive esophagitis. Other etiologies include radiation, infections, local injury 
caused by medications, pill esophagitis, and eosinophilic esophagitis (EoE) [3]. 
Patients with EoE may present with food impaction. If the esophagitis is severe and 
leads to strictures, fistulization, and perforation, patients may present with symp-
toms related to those entities.
In addition, infections can also cause swelling and irritation of the esophagus. 
Fungi, yeast, viruses, and bacteria can all set off the condition, called infectious 
esophagitis. Anyone can get it, but a person is more likely to develop it if their 
immune system is weakened [4].
The incidence of infectious esophagitis has become prevalent in immunocom-
promised patients with cancers and organ transplant because of their survival 
rates due to advances in medical practice and management techniques. The caus-
ative agent is normally Candida albicans. However, organisms like herpes simplex 
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virus (HSV) and cytomegalovirus (CMV) have often been known to invade the 
esophagus. Patients with acquired immunodeficiency syndrome (AIDS) may 
develop more fulminant forms of fungal and viral esophagitis (including human 
immunodeficiency virus [HIV] esophagitis), accentuating the need for early 
diagnosis and treatment. The purpose of this chapter is to review the clinical 
manifestations, etiology, pathophysiology, histopathology, diagnosis, treatment/
management, prevention, prognosis and other healthcare issues of infectious 
esophagitis.
2. Etiology
The causes of infectious esophagitis are many and they involve [5–13]J:
• Fungi, like C. albicans, which is the most common pathogen. However, other 
Candida group of organisms, for example C tropical, C galbarta and C parapsi-
losis have also been identified as rare causes of esophagitis.
• Other types of fungi such as Aspergillus, Histoplasma, Crytococcus,l 
Blastomyces etc.
• Viruses such as Herpex simplex (HSV), Cytomegalovirus (CMV), Varicella-
zoster virus (VZV), Epstein–Barr virus (EBV), Human papillomavirus (HPV), 
Poliovirus etc. It is important to note that people infected with the human 
immunodeficiency virus (HIV), CMV, HSV, Mycobacterium avium-intracellu-
lare are idiopathic in nature.
• Bacteria such as normal flora, Mycobacterium tuberculosis, Mavium-
intracellulare, Saphylococcus, Streptococcus, Lactobacillus, Norcadia etc.
• Parasitic agents such as chagas disease, Trypanosama cruzi, Cryptosporidium, 
Pneumocystis, Leishmania donovani etc.
The risk factors of infectious esophagitis include antibiotics and steroids use, 
chemotherapy, radiation therapy, malignancies and immunodeficiency syndromes 
like the acquired immunodeficiency syndrome (AIDS). Additional diseases linked 
to increase in the incidence of Candida esophagitis include esophageal stasis, 
alcoholism, malnutrition, and advanced age. Occasionally, Candida esophagitis can 
occur in otherwise healthy individuals with no underlying esophageal or systemic 
disease [7–13].
Additional typical risk factors such as acute onset of symptoms such as dyspha-
gia and odynophagia are also remarkable in some cases of infectious esophagitis. 
The disease may coexist with heartburn, retrosternal pain, nausea and sometimes 
vomiting. Occasionally, patients can present with abdominal pain, anorexia, weight 
loss and cough. Infectious esophagitis is frequently caused by Candida organisms. 
Other important causes include CMV and HSV infection.
Again, people presenting with generalized sepsis, low neutrophil counts, AIDS, 
burns, trauma etc., can have rare infectious esophagitis. Severe esophagitis with 
very deep ulcers and fistulous tracts to the mediastinum, pleural space, tracheo-
bronchial tree, skin and other tissues can be due to actinomycosis. The appearance 
of characteristic sulfur granules on endoscopic biopsy specimens can confirm the 
diagnosis of infectious esophagitis. The most notable risk factor for infectious 




been suggested that people can develop fungal esophagitis during the seroconver-
sion phase of the process [5, 7–13].
3. Pathophysiology
Many agents like fungi, bacteria, parasites, viruses and other microorganisms 
can cause infectious esophagitis. The disease is more prevalent in immunocom-
prised people, but it can also occur in healthy people, including adults and children 
[13, 14]. The least common of all causative agents for infectious esophagitis is 
bacteria, but the most common cause of infectious esophagitis is .
The steps involved in the pathophysiology of infectious esophagitis include:
• colonization with mucosal adherence and proliferation is the first step in 
pathophysiology of infectious esophagitis.
• impairing the host defense mechanisms
Whilst Candida Albicans is a normal component of oral flora, it can also become 
a problem if their number increases, for example, with the use of antibiotics or if 
the patient is immunosuppressed because of treatment with corticosteroids. HSV is 
the most common cause of viral esophagitis, and it infects the squamous epithelium 
leading to vesicles and then ulcerations. CMV, Epstein–Barr (EBV) and varicella-
zoster (VZV) are other viral causes of viral esophagitis.
Individuals may become susceptible to acquiring opportunistic infections like 
neutropenia, impaired chemotaxis and phagocytosis, impaired T-cell lymphocyte 
function and alteration in humoral immunity due to wide range of abnormalities in 
the host defense.
People suffering from various systemic diseases such as adrenal dysfunction, 
alcoholism, diabetes etc., and older citizens can be prone to catching infectious 
esophagitis due to altered immune function steroids, radiation, cytoxic agents and 
immune modulators can also lead to the impaired host immune function.
The mucosal protective barriers and antibiotics that suppress the normal bacte-
rial flora disruption may contribute to the invasive ability of commensal organisms 
[14]. Categories of infectious are as follows [11–14]:
i. Fungal esophagitis, for example, Candida Esophagitis
ii. Viral esophagitis, for example, HPV esophagitis and CMV esophagitis etc.
iii. Bacterial esophagitis, for example, tuberculosis, actinomycosis etc.
iv. Tuberculous esophagitis as stated in point (iii) above
v. Other infections that can cause esophagitis
Fungal overgrowth in the esophagus, or impaired cell-mediated immunity or 
both can result in the development of Candida esophagitis.
The setting of esophageal stasis leads to cause of fungal overgrowth resulting from:
a. abnormal esophageal motility like achalasia
b. scleroderma or mechanical causes such as strictures.
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Dysfunctional cell-mediated immunity can be caused by:
a. immunosuppressive treatment, for example with cytotoxic agents or steroids 
that might suppress both granulocytes and lymphocytes functions
b. Malignancy
c. AIDS
Candida esophagitis also associated with chronic mucocutaneous candidiasis, 
which is a congenital immunodeficiency state.
Diseases that interfere with esophageal peristalsis like achalasia, esophageal 
cancer and progressive systemic sclerosis may lead to fungal esophagitis.
Primarily, esophagitis caused by HPV is presented by small vesicle developments 
that rupture eventually forming superficial ulcers on the mucosa that are discrete 
in nature.
The host promotes healing of the ulcers in immunocompetent people. However 
in severely immusosuppressed people, the disease may progress from discrete areas 
of ulceration hemorrahgic esophagitis that is diffused. Candidiasis may heavily 
infect necrotic herpetic ulcers.
The esophagus is normally involved by erosion of concerned mediastinal lymph 
nodes abutting the esophagus in tuberculous esophagitis.
In addition, infection of the esophagus by bacteria occurs in the immunocom-
promised host, is usually polymicrobial, and derives from oral flora. This entity 
is underdiagnosed in severely granulocytopenic patients, given that bacteria are 
difficult to identify on routine histologic examination. In such patients, bacte-
rial infection often coexists with viral or fungal organisms that are more readily 
detected. Suppression of gastric acid production (by proton pump inhibitors) 
may predispose to bacterial and fungal esophagitis. The diagnosis is made by 
endoscopic biopsy, and in these specimens, clusters of bacteria are mixed with 
necrotic epithelial cells. Treatment consists of broad-spectrum antimicrobial 
therapy.
Although infectious esophagitis is usually caused by fungal or viral organisms, 
other rare causes include Staphylococcus, Streptococcus, Klebsiella, Blastomyces, 
Cryptosporidium, Torulopsis glabrata, and Lactobacillus acidophilus.
4. Clinical presentation
4.1 Patient history
The history findings vary based on the type of esophagitis. Esophageal food 
impaction can be the initial presentation of proton pump inhibitor (PPI)-responsive 
eosinophilic esophagitis [15].
4.2 Symptoms
Immunosuppressed people are prone to developing infectious esophagitis. Fungi 
like Candida organisms and viruses such as HPV and CMV are the most common 
causes of infectious esophagitis. The diagnosis of infectious esophagitis is supported 
by immunocompromisation, steroid treatment, systemic disease or recent antibi-
otic use. Whilst some people may not have any symptoms of infectious esophagitis, 




• Experiencing pain when swallowing
• Having trouble swallowing
• Pain in the mouth
• Pain in the chest and heartburn
• Feeling nauseous or vomiting
• Feeling feverish or experiencing chills
• Loss of appetite, anorexia, loss of weights
• Coughing
• Pain in the abdomen
• Intermittent hematemesis
As the symptoms of infectious esophagitis may mimic other diseases, it is 
important that proper investigation and diagnosis are made in order to have better 
outcome for the patients.
In people with one or more predisposing factors for Candida esophagitis, it is 
often manifested clinically by dysphagia and/or odynophagia. Symptoms differ in 
characteristics and features that differ in intensity like mild/moderate achalasia to 
severe odynophagia, which makes it very hard for sufferers to eat food or swallow-
ing. Some people may develop retrosternal pain or bleeding in the gut. However, 
some people do not have any symptoms.
Esophagitis caused by HPV is commonly present in immunosuppressed people 
with AIDS, existing cancer or long term serious diseases or people that had received 
steroids, chemotherapy or radiation treatments [13–15]. In healthy people with 
no existing medical conditions, herpes esophagitis can sometimes occur as acute 
self-limiting disease. Acute onset of severe odynophagia is usually present in people 
with herpes esophagitis. Difficulty in swallowing, pain in the chest and bleeding in 
the upper gut are other presenting symptoms in herpes esophagitis.
The development of severe odynophagia, dysphagia or both in people with 
AIDS is as a result of the manifestation of CMV. Evidence of CMV infection may be 
present in other organs and tissues like the colon, retina and liver in infected people. 
Patients may develop fear of eating sometimes in cases of severe odynophagia.
People with ulcers due to HIV normally show acute onset of severe odynophagia, 
dysphagia or both. A characteristic maculopapular rash may be visible on the upper 
half of the body if the ulcers manifest at the time of seroconversion.
People with advanced pulmonary or mediastinal tuberculosis or in immunodefi-
ciency that have disseminated tuberculosis or other mycobacterial illnesses develop 
tuberculous esophagitis.
5. Diagnosis and differential diagnoses strategies
In considering the diagnosis and differential diagnosis of infectious esophagi-
tis, it would be important to look at the diagnostic considerations and diagnosis 
considerations for the different types of infectious esophagitis in order to have 
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understandings of the various issues to note for making decisions on the suitable 
treatments for better outcomes for the patients.
5.1 Diagnostic considerations
The possibility of a systemic illness causing the esophageal manifestations 
should always be considered (for example, AIDS, scleroderma, systemic lupus 
erythematosus (SLE) and pemphigus). Similarly, cardiac causes of chest discomfort 
should also be considered, and the appropriate treatment should be given. If the 
diagnosis is unclear, admission for further evaluation is suggested. Do not misdi-
agnose cardiac chest pain as esophageal pain. Pain can be similar, particularly in 
elderly patients and women.
Conditions that may mimic symptoms of esophagitis include the following 
[12–15]:
• Coronary artery disease
• Pericarditis
• Aortic aneurysm
• Nonulcer reflux disease
• Functional dyspepsia
• Stricture
5.2 Diagnosis considerations for the different types of infectious esophagitis
The diagnosis considerations for the various types of infectious esophagitis are 
discussed below.
5.2.1 Diagnosis of Candida esophagitis
Reflux esophagitis, herpes esophagitis, superficial spreading carcinoma and 
glycogenic acanthosis, may produce findings similar to those seen in Candida 
esophagitis. However, it is also important to note that elderly people who do have 
any symptoms of the esophagus and the more rounded appearance of the mucosal 
nodules of glycogenic acanthosis do indeed present with glycogenic acanthosis, but 
the candidiasis plaques are more linear in appearance.
A nodular mucosa of reflux esophagitis can also be present in patients. However, 
the nodules are difficult to identify than those found in candidiasis, and they are 
normally infectious with the gastroesophageal junction.
Multiple plaquelike lesions in the gullet are sometimes due to herpes esophagitis, 
which is normally linked to small superficial ulcers. Cancers that are spreading 
superficially may also present as a nodular mucosa with poorly defined nodular 
borders, leading to a confluent area of disease.
The plaques of candidiasis may resemble the insoluble effervescent particles 
and debris in the gullet. Hence the performance of a double-contrast study should 





5.2.2 Diagnostic factors for herpes simplex (HSV) esophagitis
Esophagitis due to the HSV can be identified by discrete superficial ulcers in the 
upper/mid gullet in the absence of the linked plaques, in the appropriate clinical 
environment. On the other hand, Candida esophagitis ulceration usually manifests 
on a background of extensive formation of plaque. Double-contrast investigations 
can be used in the diagnosis of Candida and herpes esophagitis without performing 
an endoscopy. It is also important to undertake endoscopic evaluation for confirma-
tion of diagnosis when radiographic findings are ambiguous or when the problem 
do not respond to the treatment given to them.
Drug-induced esophagitis and Crohn disease are other causes of small super-
ficial ulcers in the upper/mid esophagus, but these diseases can be differentiated 
from infectious esophagitis via detailed and careful patient history.
5.2.3 Diagnostic factors for CMV esophagitis
Endoscopy with biopsy is the most effective diagnostic tool for CMV. Large 
punched out lesions are seen in mid esophagus on inspection. Enlarged cells in the 
sub-epithelial layer with inclusions within the cells’ nucleus and its cytoplasm can 
be seen in histological analysis of the lesions. Fluorescent staining with an immu-
noperoxidase stain is very specific in addition to the histological investigation. The 
diagnosis of CMV esophagitis cannot be made effectively with radiologic imaging 
tests like X-rays or CT scans alone, but they can be helpful in discovering of any 
resulting fistulae or strictures.
The presentation of large/giant ulcers in a patient may suggest the diagnosis of 
CMV esophagitis in AIDS patients because herpetic ulcers really becomes as big as 
those of infectious esophagitis, but giant/large ulcers can also be caused by HIV in 
HIV positive people..
Giant esophageal ulcers can also be caused by nasogastric intubation; endo-
scopic sclerotherapy; caustic injuries and oral medications, such as nonsteroidal 
anti-inflammatory drugs (NSAIDs), potassium chloride, and quinidine [13–15]. 
Efficient patient’s clinical history is normally helpful in suggesting the correct 
diagnosis of CMV esophagitis [14, 15].
Again, CMV can be transmitted through many ways, which include mother to 
child transmission, which is common after birth and spreading of CMV through 
blood or sex, but transmission via tears, saliva, and skin contact is not common. 
Therefore patient education is very important in this regard.
5.2.4 Diagnostic factors for HIV esophagitis
It is important to rule out CMV esophagitis by performing endoscopy before 
confirming the HIV esophagitis diagnosis because most HIV ulcers are not distin-
guishable from CMV ulcers on the basis of just the clinical and radiological criteria 
alone. In addition, specimens from biopsy, brushings and viral cultures from the 
esophagus may be needed in order to be certain about the diagnosis and offer the 
patient the correct treatment.
During the period of transient chills, fever, malaise and rash of early infection 
with HIV, multiple, small, aphthoid lesions are observed on patients. In addition, 
giant deep ulcers measuring several centimeters can be seen later. Large ulcers may 
be complicated by fistula formation, perforation, hemorrhage, or superinfection in 
patients.
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As most cases of HIV esophagitis responds well to oral steroids treatments, but 
CMV esophagitis is treated with toxic antiviral agents like ganciclovir, it is essential 
to differentiate between these infections. Hence endoscopic investigation should be 
undertaken before treating the patients.
5.2.5 Diagnostic factors for varicella-zoster virus (VZV) esophagitis
Severe esophagitis can be caused by Varicella-zoster virus (VZV), and finding 
its concurrent demographic lesions is extremely important to its diagnosis and also 
development of effective treatment plan for the patients.
On esophagogastroduodenoscopy (EGD), VZV has different features, which can 
range from infrequent vesicles of ulcerative lesions to a confluence of ulceration 
with necrosis. Epithelial cells with VZV display ballooning degeneration, edema 
and multinucleated giant cells with eosinophilic inclusion bodies on histologic 
investigation. In differentiating VZV from HSV, immunohistochemical staining 
utilizing monoclonal antibodies is usually helpful in the process.
5.2.6 Diagnostic factors for Epstein-Barr virus (EBV) esophagitis
Epstein–Barr virus (EBV) causes different syndromes in people. Crohn’s disease 
and ulcerative colitis are common diseases that can be manifested by EBV, but the 
incidence and prevalence of EBV are still not well stated in both immunocompetent 
and immunodeficient people, hence, it should be seriously considered in any person 
presenting with symptoms of the esophagus. EBV esophagitis in an immuuno-
competent individual is a rare occurrence, and thus represents either a primary 
infection, reactivation/reoccurrence, which si usually is characterized acute onset 
of symptoms and extensive ulcerative involvement of the upper/mid third of the 
esophagus. Oral hairy leukoplakia has similar histologic features of esophageal 
lesions linked to the EBV.
5.2.7 Diagnostic factors for human papillomavirus (HPV) esophagitis
Multiple epithelial lesions and cancers that are predominantly found on cutane-
ous mucosal surfaces are caused by the human papillomavirus (ahpv), which is a 
non-enveloped, double stranded, circular DNA virus. The virus has over 100 sub-
types, and people with persistent HPV infection, especially those with many sexual 
partners are at very high risk for contracting more subtypes of HPV. At present, the 
HPV infection can be classified as non-genital/cutaneous; mucosal or anogenital 
and epidermodysplasia verruciformis (EV).
In some cases, the clinical lesions of HPV can be visibly identifiable, but in other 
cases, latent lesions of HPV may require testing for viral deoxyribonucleic acid 
(DNA) before confirming the diagnosis. In majority of the cases, HPV infections 
are latent and most lesions manifest as warts rather than malignancy in clinic.
Nowadays, the HPV has been identifies as the etiological agent for laryngeal, 
oral, lung and anogenital cancer. HPV subtypes six and 11 are low risk and usually 
manifest with the formation of condylomata and low grade precancerous lesions. 
However, HPV 16 and 18 are high risks that are responsible for high grade intraepi-
thelial lesions, which progress to malignancies.
It is also crucial to note that HPV alone does not cause cancer, but it requires 
triggers such as folate deficiency, smoking, immunosuppression, and pregnancy 
and ultraviolet (UV) light exposure.
Esophagitis caused by HPV is an asymptomatic illness. Lesions of the disease 




look like erythematous macules, white plaques, nodules, or exuberant frondlike 
lesions. The diagnosis of HPV esophagitis is made based on histology, and koilo-
cytosis, giant cells, and cytologic atypia are visible on immunohistochemical  
stains.
5.2.8 Diagnostic factors for tuberculous esophagitis
The development of transverse or longitudinal sinus tracts or esophageal-airway 
fistulae can be as a result of the erosion of caseating nodes into the esophagus. 
People suffering from radiation esophagitis, Crohn’s disease esophageal cancer or 
some sorts of trauma also display similar fistulae and tracts, but the clinical presen-
tations of these patients normally portray the right diagnosis.
Intrinsic tuberculosis is very uncommon and it features of mucosal plaques, 
fistulae, strictures and ulcers. In a patient with tuberculosis, the development of 
difficulty in swallowing, cough and choking on swallowing indicates the involve-
ment of the esophagus.
6. Treatment and management of infectious esophagitis
Treatment of infectious esophagitis is based on the patient’s immune status, 
disease severity, and risk of complications [5, 16, 17]. The goal of medical care is to 
treat the underlying cause and minimize morbidity. The treatments strategies for 
the different types of infectious esophagitis are discussed below.
6.1 Treatment of fungal esophagitis
Antifungal drugs are normally used in the treatment of candidiasis in the throat, 
mouth or esophagus. The treatments for are categorized thus [18]:
• Active topical drugs such as oral amphotericin B, clotrimazole and nystatin
• Absorbable agents that are administered orally like fluconazole and 
itraconazole
• Agents like amphotericin B, flucytosine nad fluconazole that are administered 
parenterally
An antifungal medication that is applied to the inside of the mount between 
seven to 14 days is normally used in the treatment of mild to moderate infections 
of the throat or mouth. These drugs include clotrimazole, miconazole or nystatin. 
The most common treatment for severe fungal infections is fluconazole, which is 
an antifungal medicine that is taken by mouth or administered intravenously. If 
the patient does not respond to fluconazole, a different antifungal drug should be 
prescribed. The treatment for Candida esophagitis is fluconazole. However, another 
type of antifungal medication should be given to people who cannot tolerate flucon-
azole or who do not respond to the treatment with it.
It is important to note that treatment option chosen for a patient will depend 
on the severity of infection and the extent of the host defense impairment. For 
exam0ple, majority of immonocompetent people with fungal esophagitis can be 
treated with a topical antifungal medicine, which do not have adverse side effects, 
have only few or even any drug to drug interactions as the drugs are not absorbable 
in nature.
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6.2 Treatment of HSV esophagitis
HSV esophagitis diagnosed at endoscopy can be treated with medications such 
as acyclovir (Zovirax); valacyclovir (Valtrex); famiciclovir (Valtrex), an acyclovir 
analog; and foscamet (for acyclovir-resistant cases). Pain relief medicines bought 
over the counter at pharmacies may also help in relieving pain caused be HPV 
esophagitis. Long term prescription of antiviral drugs can also be used in the 
prevention of the development of recurrent outbreaks of HSV esophagitis.
6.3 Treatment of CMV esophagitis
CMV is similar to HSV, as it is member of the herpesviridae family of viruses. 
Induction therapy for three to six weeks is used in the treatment of CMV esophagi-
tis, but the optimal period of the treatment not yet well defined. The maintenance 
treatment for CMV is controversial. Overall, intravenously administered ganci-
clovir 5 mg/kg or foscarnet 90 mg/kg is the recommended treatment for induc-
tion therapy. As both ganciclovir and foscarnet are potent viral agents that have 
significant bone marrow and renal toxicities, extra care should be taken before they 
are prescribed to patients, by taking careful medical and drug histories form the 
patients, including any side effects they had had in the past.
It is also important to note that HIV esophagitis is treated differently from CMV 
esophagitis, but the two diseases cannot be simply separated on the basis of the 
clinical and radiographic results. Hence endoscopic investigation should be under-
taken for a confirmatory diagnosis before patients are treatment in order to achieve 
a better clinical outcome. In addition, endoscopy has over 95% sensitivity in the 
diagnosis of CMV esophagitis.
6.4 Treatment of HIV esophagitis
HIV esophagitis is treated with oral corticosteroid therapy normally for over one 
month with antiretroviral therapy for HIV in contrast to CMV esophagitis.
6.5 Treatment of VZV esophagitis
Acyclovir, famciclovir or foscarnet (for acyclovir-resistant cases) are typically 
used in the treatment of VZV esophagitis.
6.6 Treatment of EBV esophagitis
Acyclovir is used in the treatment of EBV esophagitis. In order to suppress oral 
hairy leukoplaria, long term maintenance therapy may also be required for the 
patient.
6.7 Treatment of HPV esophagitis
No treatment is normally required, as HPV esophagitis is usually asymptomatic. 
Some medicines such as systemic interferon alfa, bleomycin and etoposide have 
been used in patients’ treatments with variable outcomes.
6.8 Treatment of M. tuberculosis esophagitis
In the immunocompetent people, standard antituberculous therapy has been 




6.9 Treatment of bacterial esophagitis
In healthy individuals, infection by normal flora that is usually seen in immuno-
suppressed people are rare. Polymicrobial infections such as Staphylococcus aureus, 
Staphylococcus epidermidis, Streptococcus viridans and Bacillus species are often seen 
in patients with Bacterial esophagitis.
A broad-spectrum beta-lactam antibiotic with an aminoglycoside is used in the 
treatment of Bacterial esophagitis. It is also important to note that that the treat-
ment is adjusted based on the results of response and culture.
7. Epidemiology of infectious esophagitis
The incident of esophagitis is low in children, but esophagitis is prevalent in 
adults [19, 20], and reflux esophagitis is the most common type.
The most type of infectious esophagitis is Candida esophagitis. Incidence of 
reflux esophagitis occur monthly in up to 44% of the general population, and up to 
10% of people have daily symptoms of esophagitis [20].
In this section, we will look at the international statistics of the diseases and their 
prevalence in association with other disorders as described and discussed below.
7.1 International statistics
The prevalence of esophagitis is lower than the incidence of the symptoms of 
reflux sensation.
Patients presenting with symptoms of esophagitis to a General Practitioner (GP) 
in the United Kingdom (UK) show esophagitis rate in the range of 40–65%. The 
results of a retrospective review of results of over 800 diagnostic endoscopies in 
Hampshire, England, UK should that reflux esophagitis accounted for about 23% of 
all upper gastrointestinal diseases identified [21]. However, the incidence of infec-
tious esophagitis is small in the studied population.
Another review of the Swedish National Register estimated that the prevalence 
of esophagitis diagnosed via endoscopy is about 5% or less in people aged 55 [22], 
and prevalence has also been estimated to be about 2% in other reports [23–25]. 
Again the incidents for infectious esophagitis low as indicated in the reports.
7.2 Prevalence in association with other disorders
In people with AIDS, leukemia and lynmphoma, the prevalence of symptom-
atic infectious esophagitis is high, but it is less than 5% in the general population, 
which is low.
As noted stated previously, the most common type of infectious esophagitis 
is Candida esophagitis. The second most common infectious esophagitis is HSV 
esophagitis, which has been reported in about 1% of immunosuppressed patients, 
and in as many as 43% of the patients in autopsy investigations [23–28].
Another etiological agent for esophagitis is CMV. A big percentage of the global 
population has been exposed to CMV and asymptomatic CMV infection is common 
around the world [29, 30].
CMV esophagitis was usually discovered on post-mortem analysis prior to the 
AIDS epidemic, and the first clinical case of CMV esophagitis was reported in 
1985 [30].
CMV does not occur in immunocompetent people unlike HSV esophagitis, and 
the majority of the people with CMV esophagitis have AIDS [29, 30]. Since the 
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advent of highly active antiretroviral therapy, the incidence of CMV esophagitis like 
those of other types of infectious esophagitis has declined among people with AIDS 
[29, 30]. On the other hand, there has been reported increase of CMV esophagitis 
in people who had undergone solid organ transplant, and in whom the onset of the 
disease was delayed due to the increasing routine of early CMV prophylaxis [31].
In AIDS patients in whom no other infectious etiological factors can be identi-
fied [32–36], giant esophageal ulcers have been observed [37], which have been 
called idiopathic HIV ulcers because they are believed to be caused by HIV, as 
electron microscopic investigation had confirmed the presence of HIV-like viral 
particles in the ulcer lesions [32–37].
Most patients have been found to have chronic AIDS with CD4 counts less than 
100 cells/uL, despite the fact that some patients with HIV ulcers may have under-
gone recent seroconversion [38–41]. Ulcers associated with HIV have been under 
recognized generally, as it accounts for about 40% of all reported esophageal ulcers 
in AIDS patients [32–42].
8. Complications of infectious esophagitis
Unless a person has a medical condition that weakens his/her immunity, the 
complications of infectious esophagitis are rare, and they may include the following 
[43, 44]:
• Infection, which can spread to the other parts of the body
• Narrowing of the esophagus by scar tissue
• Bleeding from ulcers in the esophagus
• Perforation or fistula in the esophagus, including the formation of stricture
• Barrett esophagus, which occurs when the normal epithelium of the esopha-
gus is replaced with columnar epithelium that is associated with cancer 
development.
• A serious and rare complication of perforation with mediastinitis
• Inability to swallow may cause volume depletion and weight loss
• If the gastric contents are refluxed up to the level of the larynx, laryngitis, 
aspiration bronchospasm and pneumonitis may occur.
• Failure to thrive and apnea may manifest in infants and children
9. Prognosis
The prognosis of infectious esophagitis is good with quick diagnosis, including 
effective and efficient treatment. Ultimately, prognosis depends on the underlying 
disease process.
Mild symptoms of esophagitis results in minimal morbidity and mortality. 
People with moderate-to- severe symptoms may suffer anxiety and lost time from 




Esophageal strictures (typically long, smooth, tapered areas of narrowing),  
malnutrition, and, rarely, perforation or bleeding can occur as a result of complicated 
esophagitis.
Barrett esophagus and adenocarcinoma are serious gastrointestinal complica-
tions of esophagitis in addition to strictures. In children, gastric content aspiration 
is a potentially serious respiratory complication that occurs frequently, that can be 
linked to apnea, pneumonitis and bronchospasm.
Odynophagia, malnutrition, dyspnea and pain may be as a result of severe 
esophagitis. On rare occasions, death may occur as a result of life threatening bleed-
ing, but outcomes and survival in these patients are associated to the severity of 
their underlying systemic diseases.
Due to the fact that recurrence is a frequent problem in patients with  
reflux, many patients require maintenance therapy to prevent relapse of  
symptoms.
As Candida esophagitis is often self-limiting, many patients responds antifungal 
therapy [42, 43]. However, mycetoma, a fungus ball that causes obstruction may 
be formed from necrotic mucosal debris and fungal mycelia in the esophagus. The 
formation of strictures as a result of severe Candida esophagitis can also be seen 
in some patients. Rare fistula development into the tree of the bronchi, including 
ulceration and hemorrhage are other complications of infectious esophagitis, which 
will give poor outcome for the patients [43, 44].
Herpes esophagitis usually resolves spontaneously in immunocompetent 
patients within one to two weeks with conservative treatment involving analgesia 
and sedation. Rare complications of herpes esophagitis include perforation, tra-
cheoesophageal fistulas, and dissemination to other organs.
Generally, most healthy individuals with infectious esophagitis recover within 
two to four weeks with proper therapy. However, recovery in people with comprised 
immunity (immunosuppressed people) recovery may take longer due to various 
factors.
10. Patient education and preventive measures
Clinicians should work closely with people who are recovering from infectious 
esophagitis and encourage them to keep all their follow-up medical appointments in 
order to monitor their progress and treatments outcomes.
The clinicians can suggest the following steps to patients that have ongoing 
symptoms of painful or difficulty in swallowing:
• Quit smoking and the use of tobacco and its products
• Stop alcohol and caffeine consumption
• Avoid over the counter drugs such as ibuprofen, aspirin and other non-steroi-
dal anti-inflammatory drugs, which can irritate the esophagus
• Beverages and food that can cause heartburn should be avoided
• Try to lose weight if they are obsessed or overweight
• Eating smaller foods or meals more often
• Stop eating for three hours before going to bed
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• Sleeping in flat position should be avoided, and the head of the bed should be 
elevated by several inches, i.e., six inch blocks. It is also important to discour-
age patients from sleeping with extra pillows as this may increase intra-abdom-
inal pressure caused by people bending at the waist level.
The importance seeking early medical evaluation at the onset of symptoms 
should be emphasized to the patients and the general population in health educa-
tion/health promotion campaigns. In addition, the importance of taking medicines 
with plenty of water while sitting upright in order to avoid the complications of 
drug-induced esophagitis should be highlighted to the patients.
Clinicians should also avoid the prescription of certain medications like alendro-
nate in patients with obvious esophageal varices. It should also be noted that giving 
alendronate to patients who are cirrhotic could precipitate gastrointestinal bleeding 
from erosions over an esophageal varix.
11. Conclusion
Infectious esophagitis is a rare disease caused by viral, bacterial, or fungal agents 
or other organisms and infections. Patients who are immune suppressed, including 
people with granulocytopenia, lymphopenia etc., are usually prone to infections. 
Infection with Candida is the common cause of infectious esophagitis, but infections 
with HSP, bacteria and CMV are rare and accounts in up to 16% cases of infectious 
esophagitis in people with immunosuppression. Endoscopic observable ulcers with 
erythema, exudate and hemorrhage characterized bacterial esophagitis, and persistent 
symptoms include severe dysphagia and odynophagia, which may be a source of bacte-
rial sepsis that will require prompt antibiotic treatment. Thus, infectious esophagitis 
causes morbidity in patients and careful diagnosis and treatment processes need to be 
followed in order to achieve better prognosis and outcomes for sufferers.
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